According to Zacks, “Opthea Limited is a biotechnology company. It develops and commercializes therapies primarily for eye disease principally in Australia. Opthea Limited is based in South Yarra, Australia. “
Separately, Truist Financial reduced their price objective on Opthea from $25.00 to $13.00 in a research note on Wednesday.
An institutional investor recently raised its position in Opthea stock. Victory Capital Management Inc. grew its holdings in shares of Opthea Limited (NASDAQ:OPT – Get Rating) by 6.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,574,694 shares of the company’s stock after buying an additional 98,801 shares during the quarter. Victory Capital Management Inc. owned 3.58% of Opthea worth $11,811,000 at the end of the most recent reporting period. 13.29% of the stock is currently owned by institutional investors and hedge funds.
Opthea Company Profile (Get Rating)
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
- Get a free copy of the StockNews.com research report on Opthea (OPT)
- Lululemon Rises On Wave Of Price Target Increases
- The Top Is In For Infosys
- 3 Stellar Steel Stocks to Buy Now
- Is Nvidia (NASDAQ: NVDA) About To Rip Higher?
- Three Beaten Up Stocks The Insiders Are Buying
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.